|
ChatGPT Health, New CDS Guidance, and AI Starts Prescribing
January 8, 2026
|
|
|
|
|
Together with
|
|
|
|
“The era of one-size-fits-all autism therapy is ending. The highest leverage comes when we integrate medical, behavioral, and developmental care – especially in early life, when neuroplasticity is most on our side.”
|
|
Cortica Co-Founder and Chief Medical Officer Suzanne Goh
|
|
|
|
If OpenAI wasn’t already a major healthcare player, the launch of ChatGPT Health definitely just made it one.
It’s the gamechanger everyone saw coming. OpenAI even teed up the launch with a report showing that 40M people are already using ChatGPT for healthcare advice on a daily basis.
ChatGPT Health is about to take that a massive step further.
Here’s a look at the core features:
- ChatGPT Health operates inside a dedicated health environment with additional privacy layers (conversations aren’t used for model training, optional two-factor authentication).
- Users can securely upload their complete medical records (courtesy of b.well).
- Users can connect apps to inform answers (Apple Health, Function, MyFitnessPal).
- The model uses longitudinal health data, labs, and visit summaries to help spot trends.
OpenAI is moving beyond general health advice. The extra clinical context gives ChatGPT Health the ability to give better answers at scale, and that’s good news for patients.
A few of the most obvious benefits for patients include:
- Empowering them to take a more active role in their care.
- Helping them uncover trends in their overall health.
- Reducing confusion around test results.
- Reinforcing care plans between visits.
- The list could go on for a while.
ChatGPT Health isn’t actually HIPAA compliant. Then again, it doesn’t need to be.
- Consumer health apps like ChatGPT Health aren’t covered by HIPAA, and to OpenAI’s credit it appears to have done a great job with the necessary disclaimers.
- The dedicated health environment was also developed with input from 260+ physicians, and it leverages a physician-authored framework for safety, clarity, and escalation.
The question now is, who’s accountable when things go wrong? Millions of patients are about to start showing up to visits armed with advice from ChatGPT Health, which means its AI fingerprints will be all over their questions, concerns, and even clinical decisions. The tech might be ready. The governance isn’t.
- When ChatGPT Health mentions an unproven treatment and a patient follows through, or interprets a worrying lab value as benign, who carries the liability?
- OpenAI? The physicians who authored the safety framework? The patient who followed the advice? It’s tough to say, but providers – and their patients – still need a clear answer.
The Takeaway
Everyone wants a doctor in their pocket, and ChatGPT Health just filled that role for millions of patients… even if OpenAI explicitly told them it wasn’t up for the job.
|
|
Under the Hood of Navina’s AI
Navina’s AI engine harnesses over 600 proprietary algorithms to transform fragmented patient data into actionable clinical intelligence at the point of care. It’s shaped with the expertise of physicians to turn multiple data sources (EHR, HIE, claims, care gap files, etc.) into contextualized insights like suspected conditions or evidence for care gap closures – each linked back to the original source. Download the whitepaper to see examples of Navina’s AI in action.
|
|
Next Generation Ambient Tech and Agents
The ambient AI transformation is already sweeping across health systems, reducing administrative burdens and improving patient outcomes. So, what’s next? Tune into this on-demand session to learn how systems like Carle Health and Denver Health are leveraging Nabla to eliminate Pajama Time and build a future where agentic AI unlocks true workforce sustainability.
|
|
- FDA Issues CDS Guidance: The FDA issued new guidance on how it plans to regulate clinical decision support software. The guidance states that if a CDS tool meets four criteria, then it doesn’t qualify as a medical device and can avoid the stringent rules regulating them. The four criteria include: (1) the tool doesn’t process medical images (which already seems like strike one for ChatGPT Health), (2) it’s intended for displaying or analyzing medical information, (3) it’s intended for supporting HCPs with prevention, diagnosis, or treatment, and (4) HCPs aren’t intended to rely primarily on the recommendations to make decisions.
- AI Begins Prescribing Medications: Utah just became the first state to officially allow AI to renew certain prescriptions – without a single human involved. The pilot program quietly launched last month in partnership with Doctronic, a digital health startup that handles AI-powered prescription renewals for patients with chronic conditions. All eyes will now be glued to the pilot to see whether AI can safely offload sensitive workflows, and how far patients (and policymakers) will trust it to do so.
- PE Flocks to Autism: New research in JAMA Pediatrics added to the growing pile of evidence that autism services have been a magnet for both new patients and private equity alike. The study found that PE firms have acquired nearly 600 autism-focused clinics in the last decade, with 80% of those investments occurring since 2018. The PE-backed clinics were concentrated in states with higher rates of childhood autism diagnoses and fewer limits on payor coverage, which is right in line with the ABA therapy boom that Trilliant Health highlighted last week.
- Oral GLP-1s Have Arrived: The hottest drug class in the world just got a whole lot hotter, with Novo Nordisk receiving FDA approval for its oral formulation of Wegovy (semaglutide) for weight management and cardiovascular risk reduction. That makes Wegovy the first oral GLP-1 approved for obesity treatment, and the once-daily pill is already hitting the U.S. market at $149/month for the 1.5mg starting dose. Results from Novo’s Oasis-4 trial showed that patients achieved 16.6% average weight loss versus 2.7% with placebo, comparable to injectable Wegovy results.
- The Art of the Pharma Deal: Nine of the world’s biggest pharmaceutical companies – Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GSK, Merck, Novartis, Genentech, and Sanofi – reached agreements with the Trump administration to lower certain drug costs in exchange for tariff relief. The “most favored nation” agreements will match U.S. prices with the lowest prices in developed countries, meaning 60% to 90% reductions on a range of popular medications. The drugs will be available through direct-to-patient programs, Medicaid, and the new TrumpRx platform.
- Tebra Raises $250M: Tebra just closed $250M in a mix of equity and debt financing to accelerate AI innovation across its “all-in-one EHR+ platform” for private practices.The new funding will fuel the rapid deployment of AI capabilities for every aspect of practice management, including the EHR, revenue cycle management, patient experience, and practice marketing. Tebra’s EHR+ platform is designed to go beyond a “System of Record” to deliver a “System of Action,” and the fresh funds will help it leverage AI to hit that goal.
- Predicting Disease Risk from Sleep: A new study in Nature Medicine suggests that a novel AI model can predict over a hundred different diseases from a single night of sleep. Stanford researchers trained the SleepFM foundation model on 585k hours of sleep recordings from 65k patients, combining brain, heart, and breathing signals to predict future disease risk. SleepFM was shown to accurately predict 130 conditions with one night of sleep data, including dementia (C-Index 0.85), myocardial infarction (0.81), chronic kidney disease (0.79), stroke (0.78), and atrial fibrillation (0.78).
- Inova’s Notable Partnership: Inova Health is teaming up with Notable to address rising administrative burden and staffing constraints with scalable AI automation. The Virginia-based health system will leverage Notable’s AI platform to automate manual workflows weighing down its staff, with an initial focus on revenue cycle and patient access. The first stage of the partnership will see Inova utilize Notable’s low-code Flow Builder and customizable AI Agents across critical areas like ADRs, denials, and closed-loop referral management.
- Valerie Series A: Valerie Health hauled in $30M of Series A funding to bring AI front offices to independent provider groups. The platform embeds AI agents with humans-in-the-loop directly inside a clinic’s existing workflows to fully automate repetitive tasks like referrals, faxes, and scheduling. Valerie’s unique “AI-plus-human” loop reportedly ensures ~100% accuracy within each clinic’s systems to turn error-prone manual processes into auditable automations.
- Nabla + Advanced Machine Intelligence: Nabla is kicking off the year with a major new AI ally after landing an exclusive partnership with Advanced Machine Intelligence, an AI research company founded by Meta’s former chief AI scientist Yann LeCun. The partnership will give Nabla first access to AMI’s emerging “world model” technologies, which are apparently a significant leap forward in AI safety for high stakes settings like healthcare. Nabla CEO Alex LeBrun has a long history working with LeCun and is stepping over to serve as the chief executive at AMI while staying on as chairman of Nabla.
|
|
Enrollment Timelines, State by State
Provider enrollment delays are shaping access to care, revenue timelines, and even workforce strategy. Ever wonder how they’re impacting organizations near you? Check out Medallion’s 2025 Geography of Payor Enrollments to see state-by-state enrollment times, how delays are compounding workforce shortages, and why you should factor this into your 2026 planning.
|
|
Using AI to Democratize Performance Data
You’re tracking clinical performance metrics – HACs, LoS, FCOTS, and more – but does tracking translate to better patient care? Watch the on-demand recap of C8 Health’s recent expert roundtable to learn how leading institutions leverage AI to bring quality data to the bedside. Plus: See how this approach saved UTMB Health over $109k in three months.
|
|
- 10 Bold Predictions for Healthcare AI: If 2024 was the year of proof-of-concept and 2025 was the year of early adoption and scale, 2026 is shaping up to be something different. This year, AI will become expected infrastructure and simply part of how healthcare gets done. Read these 10 predictions from clinical leaders, health system executives, and researchers shaping the next phase of the field on how the AI conversation will change in 2026.
- Scale Remote Patient Monitoring With BPM Pro 2: BPM Pro 2 is the next generation of cellular blood pressure monitors, empowering care teams to scale remote patient monitoring and streamline operations. Discover why leading providers are choosing BPM Pro 2 to collect highly precise measurements and enrich data with Patient Insights from their daily lives.
|
|
|
|
|
